CAM
KALV

ClariVest Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

ClariVest Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$673K Hold
57,096
– – 0.07% 324
2024
Q2 		$673K Buy
57,096
+1,535
+3% +$17.9K 0.07% 324
2024
Q1 		$659K Buy
+55,561
New +$741K 0.07% 337

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ClariVest Asset Management's KALV Position: Q3 2024 in Review

ClariVest Asset Management held its KalVista Pharmaceuticals (KALV) position steady in Q3 2024 at 57,096 shares worth $673K. The position accounts for 0.07% of the portfolio, ranked #324.

ClariVest Asset Management first reported a position in KALV in Q1 2024 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

  • ClariVest Asset Management held 57,096 shares of KalVista Pharmaceuticals worth $673K as of Q3 2024.
  • ClariVest Asset Management left its KalVista Pharmaceuticals share count unchanged in Q3 2024.
  • KalVista Pharmaceuticals made up 0.07% of ClariVest Asset Management's portfolio in Q3 2024, its #324 holding.
  • ClariVest Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.